| MeSH term | MeSH ID | Detail |
|---|---|---|
| Cell Transformation, Neoplastic | D002471 | 126 associated lipids |
| Thyroid Neoplasms | D013964 | 33 associated lipids |
| Carcinoma, Hepatocellular | D006528 | 140 associated lipids |
| Fibrosis | D005355 | 23 associated lipids |
| Leukemia, Myeloid, Acute | D015470 | 19 associated lipids |
| Hypergammaglobulinemia | D006942 | 9 associated lipids |
| Glioblastoma | D005909 | 27 associated lipids |
| Nephritis | D009393 | 19 associated lipids |
| HIV Infections | D015658 | 20 associated lipids |
| Neurilemmoma | D009442 | 10 associated lipids |
(e,z)-farnesol
(e,z)-farnesol is a lipid of Prenol Lipids (PR) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 3613 references associated with (e,z)-farnesol in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for (e,z)-farnesol
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with (e,z)-farnesol
PubChem Biomolecular Interactions and Pathways
All references with (e,z)-farnesol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Yue W et al. | Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells. | 2007 Aug-Sep | J. Steroid Biochem. Mol. Biol. | pmid:17616457 |
| Hasmim M et al. | Zoledronate inhibits endothelial cell adhesion, migration and survival through the suppression of multiple, prenylation-dependent signaling pathways. | 2007 | J. Thromb. Haemost. | pmid:17059425 |
| Lazzerini PE et al. | Rosuvastatin inhibits spontaneous and IL-1β-induced interleukin-6 production from human cultured osteoblastic cells. | 2013 | Joint Bone Spine | pmid:22999910 |
| Khwaja A et al. | The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid. | 2005 | Kidney Int. | pmid:16014024 |
| Fong C et al. | Monodisperse nonionic isoprenoid-type hexahydrofarnesyl ethylene oxide surfactants: high throughput lyotropic liquid crystalline phase determination. | 2011 | Langmuir | pmid:21294552 |
| Henriques M et al. | Effect of farnesol on Candida dubliniensis morphogenesis. | 2007 | Lett. Appl. Microbiol. | pmid:17257261 |
| Satoh T et al. | The effects of pravastatin, an HMG-CoA reductase inhibitor, on cell viability and DNA production of rat hepatocytes. | 1996 | Life Sci. | pmid:8831797 |
| Chaudhary SC et al. | Chemopreventive effect of farnesol on DMBA/TPA-induced skin tumorigenesis: involvement of inflammation, Ras-ERK pathway and apoptosis. | 2009 | Life Sci. | pmid:19470390 |
| Duncan RE and Archer MC | Farnesol decreases serum triglycerides in rats: identification of mechanisms including up-regulation of PPARalpha and down-regulation of fatty acid synthase in hepatocytes. | 2008 | Lipids | pmid:18509688 |
| Leonhardt I et al. | The fungal quorum-sensing molecule farnesol activates innate immune cells but suppresses cellular adaptive immunity. | 2015 | MBio | pmid:25784697 |
| Tashiro M et al. | Pravastatin inhibits farnesol production in Candida albicans and improves survival in a mouse model of systemic candidiasis. | 2012 | Med. Mycol. | pmid:21954955 |
| Cordeiro RA et al. | Minimum inhibitory concentrations of amphotericin B, azoles and caspofungin against Candida species are reduced by farnesol. | 2013 | Med. Mycol. | pmid:22712455 |
| Sarazin A et al. | In vitro pro- and anti-inflammatory responses to viable Candida albicans yeasts by a murine macrophage cell line. | 2010 | Med. Mycol. | pmid:20438293 |
| Kim SY et al. | Inhibition effect of new farnesol derivatives on all-trans-retinoic acid metabolism. | 2001 | Metab. Clin. Exp. | pmid:11699057 |
| Wang C et al. | Engineered heterologous FPP synthases-mediated Z,E-FPP synthesis in E. coli. | 2013 | Metab. Eng. | pmid:23608473 |
| Rotblat B et al. | The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer. | 2008 | Meth. Enzymol. | pmid:18374183 |
| Berzat AC et al. | Using inhibitors of prenylation to block localization and transforming activity. | 2006 | Meth. Enzymol. | pmid:16757354 |
| Epand RM et al. | Lipid-mediated a-factor interactions with artificial membranes. | 1995 | Meth. Enzymol. | pmid:7651149 |
| Deveau A and Hogan DA | Linking quorum sensing regulation and biofilm formation by Candida albicans. | 2011 | Methods Mol. Biol. | pmid:21031315 |
| Dudler T and Gelb MH | Probing the role of H-Ras lipidation for signaling functions in Xenopus laevis oocytes. | 1999 | Methods Mol. Biol. | pmid:10399152 |